Cite
HARVARD Citation
Segurado, O. et al. (2022). Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies – a spotlight on hemophilia. Expert opinion on biological therapy. pp. 1091-1098. [Online].